Robinson Sophie, Kissane David W, Brooker Joanne, Michael Natasha, Fischer Jane, Franco Michael, Hempton Courtney, Sulistio Merlina, Pallant Julie F, Clarke David M, Burney Susan
Department of Psychiatry, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.
School of Psychological Sciences, Monash University, Clayton, Australia.
Cancer. 2016 Jul 15;122(14):2251-9. doi: 10.1002/cncr.30015. Epub 2016 May 12.
The Demoralization Scale (DS) was initially validated in 2004 to enable the measurement of demoralization in patients with advanced cancer. Subsequent shortcomings indicated the need for psychometric strengthening. Here, the authors report on the refinement and revalidation of the DS to form the DS-II, specifically reporting the scale's internal validity.
Patients with cancer or other progressive diseases who were receiving palliative care (n = 211) completed a revised version of the 24-item DS and a measure of symptom burden (the Memorial Symptom Assessment Scale). Exploratory factor analysis and Rasch modeling were used to evaluate, modify, and revalidate the scale, providing information about dimensionality, suitability of response format, item fit, item bias, and item difficulty. Test-retest reliability was examined for 58 symptomatically stable patients at a 5-day follow-up.
Exploratory factor analysis supported a 22-item, 2-component model. Separate Rasch modeling of each component resulted in collapsing the response option categories and removing 3 items from each component. Both final 8-item subscales met Rasch model expectations and were appropriate to sum as a 16-item total score. The DS-II demonstrated internal consistency and test-retest reliability (Meaning and Purpose subscale: α = .84; intraclass correlation [ICC] = 0.68; Distress and Coping Ability subscale: α = .82; ICC = 0.82; total DS: α = .89; ICC = 0.80).
The DS-II is a 3-point response, self-report scale comprising 16 items and 2 subscales. Given its revalidation, psychometric strengthening, and simplification, the DS-II is an improved and more practical measure of demoralization for research and clinical use. External validation of the DS-II will be reported subsequently. Cancer 2016;122:2251-9. © 2016 American Cancer Society.
失志量表(DS)最初于2004年得到验证,用于测量晚期癌症患者的失志情况。随后发现的不足之处表明需要对其心理测量学特性进行强化。在此,作者报告了DS的修订及重新验证过程,以形成DS-II,并特别报告了该量表的内部效度。
接受姑息治疗的癌症或其他进展性疾病患者(n = 211)完成了24项DS的修订版以及症状负担测量工具(纪念症状评估量表)。采用探索性因素分析和Rasch模型来评估、修改并重新验证该量表,提供有关维度、反应格式的适用性、项目拟合度、项目偏差和项目难度的信息。对58名症状稳定的患者进行了为期5天的重测信度检查。
探索性因素分析支持一个包含22个项目、两个分量表的模型。对每个分量表分别进行Rasch模型分析,结果是合并反应选项类别并从每个分量表中删除3个项目。最终的两个8项分量表均符合Rasch模型预期,适合作为16项总分进行相加。DS-II显示出内部一致性和重测信度(意义与目的分量表:α = 0.84;组内相关系数[ICC] = 0.68;痛苦与应对能力分量表:α = 0.82;ICC = 0.82;DS总分:α = 0.89;ICC = 0.80)。
DS-II是一个采用3级反应的自评量表,包含16个项目和两个分量表。鉴于其重新验证、心理测量学特性强化及简化,DS-II是用于研究和临床的失志情况的一种改进且更实用的测量工具。DS-II的外部验证将随后报告。《癌症》2016年;122:2251 - 9。© 2016美国癌症协会。